Immune checkpoint inhibitors (ICIs) have revolutionized the field of cancer immuno-oncology. ICIs act on cancer cells by blocking the interaction between immune checkpoint proteins on immune cells and ...

Treatment with Tagrisso after chemoradiation resulted in patients with EGFR-mutant stage 3 non-small cell lung cancer being nearly three times less likely to experience disease progression when ...

Timing of consolidation durvalumab significantly impacts survival for patients with locally advanced non-small cell lung ...

A daily pill called osimertinib (Tagrisso) is delivering far longer cancer control for adults with unresectable stage 3 EGFR-mutated non-small cell lung cancer after chemoradiation and is now ...

Please provide your email address to receive an email when new articles are posted on . “Interest in organ preservation strategies for patients with rectal cancer persists,” Paul B. Romesser, MD, ...

WASHINGTON — Reduced doses of radiation therapy and immunotherapy did not work as well as the standard chemoradiation for early-stage HPV-associated oropharyngeal cancer, in a new study. These ...

Patients with unresectable stage 3 non-small cell lung cancer treated with Tecentriq before and following chemoradiation may derive a survival benefit. Tecentriq (atezolizumab) administered before and ...

A bladder-specific 15-gene transcriptomic signature distinguishes patients with MIBC at high risk for poor chemoradiation therapy outcomes. A 15-gene transcriptomic signature has the potential to ...

An early-phase, dose-escalation study of a hypofractionated approach to concurrent chemoradiation using an an adaptive stereotactic ablative radiotherapy (SABR) boost showed promising results in ...

BARCELONA – Adding preoperative chemoradiation to standard-of-care perioperative chemotherapy did not improve overall or progression-free survival in patients with resectable adenocarcinoma of the ...